Visiomed (ASX: VSG) is readying itself to commence marketing and distribution of its Funhaler device worldwide, although it is still awaiting US FDA clearance for the product. [ + ]

According to eminent Australian stem cell researcher Prof Alan Trounson, stem cell science is in a great place at the moment. [ + ]

Amrad (ASX: AML) will receive its third US$3 million payment from Merck & Co after reaching another preclinical milestone in the development of new asthma therapies based on the IL-13 receptor. [ + ]

Amrad (ASX: AML) chairman Bob Moses told shareholders at the company's AGM that the company remained significantly undervalued, even though it had successfully restructured and refocused its portfolio to concentrate on inflammation and cancer, and spinning out the anti-infectives projects into Avexa. [ + ]

Genzyme has posted a third-quarter profit compared to a loss last year, when it took a big charge associated with an acquisition. [ + ]

Shares in Brisbane drug-developer Alchemia (ASX:ACL) rose 50 per cent to $0.80 today, on the back of news that it would be targeting antibiotic-resistant "superbugs" with a novel class of synthetic molecules that disrupt cell-wall synthesis in bacteria. [ + ]

Mice -- and perhaps humans -- can thrive when large amounts of so-called junk DNA are deleted from their genome, according to results of experiments reported in the October 21 issue of Nature. [ + ]

Brisbane biotech Benitec (ASX:BLT) shares were up 8 per cent to $0.65 today after it announced it had granted a worldwide, non-exclusive licence to Panomics, of Redwood City in California. The licence allows Panomics to make and sell products that exploit Benitec's patented DNA-directed RNAi gene-silencing technology. [ + ]

Newly-listed Proteome Systems (ASX: PXL) has entered into a collaboration with researchers at the Westmead Children's Hospital and Westmead Millennium Institute to develop diagnostics for the early diagnosis and monitoring of ovarian cancer. [ + ]

Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema. [ + ]

Cryptome Pharmaceuticals (ASX: CRP) has announced that CEO Jeffrey Travis has resigned for personal reasons. [ + ]

Rockeby's (ASX:RBY) laboratory-based SysCan tests for Candida antibody levels is likely to be useful for diagnosing the infection in children, a trial in Singapore has found. [ + ]

The FDA has approved a new injectable gel, made by Genzyme and marketed by Inamed, that can be used to temporarily fill the deepest facial wrinkles. [ + ]

Melbourne brain-drug developer Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) will move its is lead Alzheimer's disease drug PBT-1 (clioquinol) into a Phase II/III clinical trial in the first half of next year, with the aim of carving up to three years from the time required to deliver the drug to the clinic. [ + ]

Six weeks after filing 5600 pages of Investigational New Drug application for a Phase II trial of its ThrombioView blood-clot imaging technology, Agenix [ASX: AGX, NASDAQ OTC: AGXLY] has been given the go-ahead by the US Food and Drug Administration. [ + ]